Management of Large-Vessel Vasculitis With FDG-PET

A Systematic Literature Review and Meta-Analysis

Michael Soussan, MD, Patrick Nicolas, PharmD, PhD, Catherine Schramm, PhD, Sandrine Katsahian, MD, PhD, Gabriel Pop, MD, Olivier Fain, MD, and Arsene Mekinian, MD

Abstract: We aimed to clarify the role of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in the management of large-vessel vasculitis (LVV), focusing on 3 issues which are as follows: describe and determine the different FDG-PET criteria for the diagnosis of vascular inflammation, the performance of FDG-PET for the diagnosis of large-vessel inflammation in giant cell arteritis (GCA) patients, and the performance of FDG-PET to evaluate the disease inflammatory activity in Takayasu arteritis (TA) patients.

MEDLINE, Cochrane Library, and EMBASE database were searched for articles that evaluated the value of FDG-PET in LVV, from January 2000 to December 2013. Inclusion criteria were American College of Rheumatology criteria for GCA or TA, definition PET positivity threshold, and >4 cases included. Sensitivity (Se) and specificity (Sp) of FDG-PET for the diagnosis of large-vessel inflammation were calculated from each included individual study, and then pooled for meta-analysis with a random-effects model.

Twenty-one studies (413 patients, 299 controls) were included in the systematic review. FDG-PET showed FDG vascular uptake in 70% (288/413) of patients and 7% (22/299) of controls. Only vascular uptake equal to or higher than the liver uptake was significantly different between GCA/TA patients and controls (P < 0.001). The meta-analysis of GCA patients (4 studies, 57 patients) shows that FDG-PET has high Se and Sp for the diagnosis of large-vessel inflammation in GCA patients in comparison to controls, with a pooled Se at 90% (95% confidence interval [CI], 79%–93%) and a pooled Sp at 98% (95% CI, 94%–99%). The meta-analysis of TA patients (7 studies, 191 patients) shows that FDG-PET has a pooled Se at 87% (95% CI, 78%–93%) and Sp at 73% (95% CI, 63%–81%) for the assessment of disease activity in TA, with up to 84% Sp, with studies using National Institutes of Health criteria as the disease activity assessment scale.

FDG-PET showed good performances in the diagnosis of large-vessel inflammation, with higher accuracy in GCA patients than in TA patients. Although a vascular uptake equal to or higher than the liver uptake appears to be a good criterion for the diagnosis of vascular inflammation, further studies are needed to define the threshold of significance as well as the clinical significance of the vascular uptake.

INTRODUCTION

Large-vessel vasculitis (LVV) comprises non-necrotizing granulomatous vasculitis, with mainly 2 separate conditions: giant cell arteritis (GCA) and Takayasu arteritis (TA). Although these 2 conditions are characterized by the inflammation of aorta and its main branches, several substantial differences exist in clinical practice. For GCA, the diagnosis of large-vessel inflammation could be challenging in patients with systemic constitutional signs, unexplained inflammatory syndrome, or negative temporal artery biopsy (TAB). In patients with early-stage TA, the diagnosis of vascular inflammation with conventional imaging could be challenging, whereas in late-stage TA the persistent underlying inflammation could be difficult to assess and a reliable tool for this task is still lacking.

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a hybrid imaging method with growing interest for the diagnosis of various inflammatory conditions such as sarcoidosis, vasculitis, and infections. Several studies assessed the interest of FDG-PET for the diagnosis of LVV and the correlation to the disease activity. Authors stated that FDG-PET is highly effective in assessing the disease activity and the extent of LVV. Yet, the conclusions of these studies are biased by the inclusion of small number of patients with various inclusion criteria and even polymyalgia rheumatica without GCA. In addition, no definite consensus criteria exist to define the presence of vascular inflammation by FDG-PET in LVV and different parameters such as visual or semiquantitative methods have been reported. Regardless, the assessment of persistent vascular inflammation in TA, PET studies used various definitions of clinical disease activity, and large studies are still lacking.

In this systematic review and meta-analysis, we aimed to clarify the role of FDG-PET in the management of GCA and TA patients, focusing our research on 3 issues: describe and determine the different FDG-PET criteria for the diagnosis of vascular inflammation, the performance of FDG-PET for the diagnosis of large-vessel inflammation in GCA patients, and the

Medicine • Volume 94, Number 14, April 2015 www.md-journal.com | 1
performance of FDG-PET to evaluate the disease inflammatory activity in TA patients.

**METHODS**

**Data Sources and Searches**

A quantitative systematic review covering the period from January 2000 to December 2013 was undertaken by a comprehensive search of English and French medical literature with use of PubMed (MEDLINE), Web of science, and EMBASE database to identify original articles on the evaluation of FDG-PET in patients with GCA and TA. The literature search was conducted by AM and MS using the following terms: positron emission tomography, PET, FDG-PET, PET/CT, PET-CT, vasculitis, aortitis, giant cell arteritis, Horton disease, Takayasu disease, Takayasu arteritis, large-vessel vasculitis and large-vessel arteritis. Ethical approval was not necessary, as this study was based on published data.

**Study Selection**

To be included in the study, the published articles had to fulfill the following criteria for GCA: American College of Rheumatology (ACR) diagnostic criteria and/or positive TAB and for TA: ACR diagnostic criteria and/or Ishikawa modified Sharma criteria10; description of FDG-PET positivity criteria; and >4 included patients. To be eventually included in the quantitative meta-analysis, each study had to report the complete 2 × 2 contingency table or give full data to build it. All articles were independently reviewed by AM and MS, first separately and then together to verify the inclusion criteria.

**Data Extraction**

The 2 co-authors (AM and MS) reviewed together the selected articles to extract the following data: first author, year of publication, number of patients and controls, controls underlying disease, study design, geographic provenance of the study population, age, sex ratio, acute-phase reactants (erythrocyte sedimentation rate [ESR] and C-reactive protein), disease activity assessment (TA), disease activity status, and treatments before FDG-PET or time from treatment to PET realization. For TA, the criteria used for the assessment of disease activity were specified: National Institutes of Health (NIH) scale or other activities assessment.11 PET data were analyzed as follows: number of positive PET (using authors’ criteria); type of PET criteria for the diagnosis of vasculitis: visual analysis or semi-quantitative analysis (maximum standardized uptake value [SUVmax] or SUVmax normalized by standardized uptake value [SUV] of liver or inferior vena cava [IVC]); and uptake threshold.

Studies with TA providing individual data regarding clinical activity, acute phase reactants (ESR and/or C-reactive protein), PET visual grade, and SUVmax were identified. These individual data were pooled in order to study the relationship between clinical/biological data and PET results.

**Data Synthesis and Analysis**

Descriptive statistics included the mean (standard deviation) for continuous variables and frequencies (percentages) for categorical variables. For each included study in the meta-analysis, we extracted or built the 2 × 2 table of true-positive, false-positive, true-negative, and false-negative results in order to calculate test sensitivity (Se) and specificity (Sp). When any observed count was zero, we used a continuity correction of 0.5, applied to all 4 cells of the study. The PET imaging was the index test while the diagnostic criteria of the disease (GCA or TA) or scales of disease activity for TA were considered as the reference diagnostic tests. Then, we performed univariate meta-analyses of Se and Sp to synthesize logit-transformed Se and Sp values separately, testing for homogeneity with a χ² test. In addition, likelihood ratios (LRs) and diagnostic odds ratios were pooled by the DerSimonian method (random-effects model). The software Meta-DiSc version 1.4 was used to perform this meta-analysis technique.12 In addition to this meta-analysis, additional statistical comparisons between accordingly continuous or qualitative variables were made with JMP version 10.0 (SAS Institute Inc, Cary, NC). All P values were 2 tailed, and P < 0.05 was considered to reflect a statistical significance.

**RESULTS**

**Literature Search and Analysis**

The literature search yielded 264 citations of PET and PET/computed tomography (CT) in LVV, of which 106 studies corresponding to original articles were assessed for eligibility. Twenty-one studies were included in the systematic review. Among the 21 studies, 4 were included in the first meta-analysis to determine the value of FDG-PET for the diagnosis of large-vessel vascular inflammation in GCA, and 7 were included in the second meta-analysis to determine the value of FDG-PET to detect the vascular inflammation in TA with active disease (see Flow Diagram).

The systematic review (21 studies) provided 413 cases of LVV, including 127 cases of GCA (8 studies), 197 cases of TA (8 studies), and 9 cases with LVV (5 studies) that did not provide sufficient data to discriminate between GCA and TA.13–17 The control group included 299 patients: 226 were oncologic patients, 31 suffering from other conditions (infections n = 18, rheumatoid arthritis n = 6, and small vessel vasculitis n = 5), and 44 were undefined. At the time of PET study, 38% (156/413) of patients were under corticosteroid and/or immunosuppressive treatment.

The parameter used to detect the vascular inflammation with FDG-PET and the thresholds used to define the presence of vascular inflammation were different among the studies (Table 1). Visual analysis was used in 19/21 studies, with mostly the liver uptake used as the reference (17/19 studies), and threshold for the presence of vascular inflammation defined as slight vascular uptake (≤ liver uptake) in 6/17 studies, moderate uptake (= liver uptake) in 9/17 studies, or intense uptake (> liver uptake) in 2/17 studies (Table 1). The semi-quantitative analysis was used in 2/21 studies to define the presence of LVV: SUVmax or SUVmax normalized by SUV of liver or IVC.

**Descriptive Analysis of FDG-PET in GCA/TA: Systematic Review**

FDG-PET detected a vascular arterial uptake in 70% (288/413) of patients with GCA/TA and 7% (22/299) of controls (P < 0.05) (Table 2). The detection of vascular arterial uptake was more frequent in GCA patients than in TA patients (110/127 = 87% vs 114/197 = 58%, respectively, P < 0.0001).

Considering the visual analysis using the liver as a reference, only moderate and high uptakes (≥ liver uptake) were significantly more frequent in GCA/TA patients than in controls
TABLE 1. Studies Included in the Literature Review and Meta-Analysis: Descriptive Characteristics and Details of the Inclusion Criteria

| Author          | Type   | No. of Patients | Diagnostic Criteria | PET Parameter and Threshold for the Diagnosis of Vascular Inflammation | SQA | Controls (n) |
|------------------|--------|-----------------|---------------------|---------------------------------------------------------------------|-----|--------------|
| Blockmans18       | GCA    | 13              | TAB (+)             | PET: VA or moderate uptake (liver uptake)                           | No  | Yes (44)     |
| Blockmans19,19   | GCA    | 35              | TAB (+)             | PET: VA or slight uptake (liver uptake)                            | No  | No           |
| Hautzel20         | GCA    | 18              | ACR                 | PET: SQA or vascular SUV<sub>max</sub>/liver SUV<sub>max</sub> ratio > 1 | Yes | Yes (36)     |
| Both31            | GCA    | 25              | ACR                 | PET: VA or slight uptake (liver uptake)                            | No  | No           |
| Czihal22          | GCA    | 6               | ACR                 | PET: VA or moderate uptake (liver uptake)                          | No  | No           |
| Forster23         | GCA    | 11              | ACR                 | PET: VA or moderate uptake (liver uptake)                          | No  | Yes (18)     |
| Morinobu24        | GCA    | 4               | ACR                 | N/A: moderate uptake (liver uptake)                                | No  | No           |
| Mellert25         | GCA    | 15              | ACR                 | PET: VA or intense uptake (liver uptake) for ascending aorta and large branches, moderate uptake (liver uptake) for other vascular segments | No  | Yes (78)     |
| Scheel16          | GCA and TA | 8           | ACR (4 / 8)         | N/A: VA or slight uptake (liver uptake)                            | No  | No           |
| De Leeuw13        | GCA and TA | 5           | ACR                 | PET: VA or slight uptake (lung uptake)                             | No  | No           |
| Walter17          | GCA and TA | 26          | ACR                 | PET: VA or moderate uptake (liver uptake)                          | No  | Yes (26)     |
| Lehmann15         | GCA and TA | 20          | ACR                 | PET/CT: VA or intense uptake (liver uptake) for aorta and slight uptake for other vascular segments | Yes | Yes (20)     |
| Fuchs14           | GCA and TA | 30          | ACR                 | PET/CT: VA or moderate uptake (liver uptake)                       | No  | Yes (31)     |
| Kobayashi26       | TA     | 14              | ACR                 | PET: VA or heterogeneous increased uptake                          | Yes | Yes (6)      |
| Andrews27         | TA     | 6               | ACR                 | PET: VA or slight uptake (liver uptake)                            | No  | No           |
| Webb28            | TA     | 18              | ACR                 | PET: VA or slight uptake (liver uptake)                            | No  | No           |
| SG Lee29          | TA     | 32              | ACR                 | PET/CT: VA or moderate uptake (liver uptake)                       | No  | No           |
| Arnaud30          | TA     | 28              | ACR                 | PET/CT: VA or slight uptake (liver uptake)                         | Yes | No           |
| K-H Lee31         | TA     | 38              | ACR                 | N/A: VA or moderate uptake (liver uptake)                          | Yes | No           |
| Tezuka32          | TA     | 39              | ACR                 | PET/CT: SQA or vascular SUV<sub>max</sub>/IVC SUV<sub>max</sub> > 2.1  | Yes | Yes (40)     |
| Karapolat33       | TA     | 22              | ACR                 | PET/CT: VA or moderate uptake (liver uptake)                       | Yes | No           |

ACR = American College of Rheumatology, CT = computed tomography, GCA = giant-cell arteritis, IVC = inferior vena cava, LVV = large-vessel vasculitis, N/A = not available, PET = positron emission tomography, TA = Takayasu arteritis, TAB = temporal artery biopsy, VA = visual analysis, SQA = semiquantitative analysis, SUV<sub>max</sub> = maximum standardized uptake value.

TABLE 2. Characteristics of Patients With LVV, GCA, TA, and Controls Included in the Systematic Review

| All Patients | GCA | TA | Controls |
|--------------|-----|----|----------|
| N            | 413 | 127| 197      | 299      |
| Age, y       | 55 ± 4 | 69 ± 7 | 36 ± 13 | 62 ± 9 |
| Sex (female) | 324 (78%) | 91 (72%) | 163 (83%) | 185 (62%) |
| ESR, mm/h    | 64 ± 26 | 86 ± 18 | 44 ± 37 | 85 ± 31 |
| C-reactive protein, mg/L | 56 ± 37 | 75 ± 45 | 36 ± 39 | 59 ± 39 |
| Corticosteroid and/or IS treatment | 156/413 (38%) | 110/127 (35%) | 114/197 (58%) | 22/299 (7%) |
| Positive PET<sup>1</sup> | 288/413 (70%) | 110/127 (87%) | 114/197 (58%) | 22/299 (7%) |
| SUV<sub>max</sub> | 3.2 ± 2.1 (n = 95) | 3.0 ± 2 (n = 36) | 2.3 ± 0.55 (n = 17) | N/A |
| SUV<sub>max</sub> ratio<sup>1</sup> | 1.22 ± 0.45 (n = 67) | 1.21 ± 0.3 (n = 16) | 1.22 ± 0.5 (n = 51) | N/A |
| Visual grades | n = 108 | n = 19 | n = 63 | n = 108 |
| No uptake    | 11 (10%) | 0 (0%) | 7 (11%) | 40 (37%) |
| Slight uptake (<liver uptake) | 7 (6%) | 1 (5%) | 5 (8%) | 49 (45%) |
| Moderate uptake (liver uptake) | 42 (40%) | 4 (21%) | 23 (37%)<sup>2</sup> | 15 (14%) |
| High uptake (liver uptake) | 48 (44%)<sup>2</sup> | 14 (74%)<sup>2</sup> | 28 (44%)<sup>2</sup> | 4 (4%) |

ESR = erythrocyte sedimentation rate, GCA = giant cell arteritis, IS = immunosuppressive, N/A = not available, PET = positron emission tomography, SUV<sub>max</sub> = maximum standardized uptake value, TA = Takayasu arteritis.

<sup>1</sup> Significantly different compared with controls (P < 0.05).

<sup>2</sup> According to author’s threshold (see Table 1).

<sup>3</sup> Maximum standardized uptake value.

<sup>4</sup> Vascular SUV<sub>max</sub>/liver SUV.
FDG-PET for the Diagnosis of Large-Vessel Inflammation in GCA

Four studies were included in this meta-analysis, with 57 patients with GCA and 176 controls (Figure 1, Table 3). FDG-PET parameter for the diagnosis of large-vessel inflammation was a visual analysis in 3 studies [threshold defined as a moderate uptake (n = 2) or intense uptake (n = 1)], or a semiquantitative analysis in 1 study (SUV\textsubscript{max}/liver SUV\textsubscript{max} > 1). Compared with controls, the pooled Se of FDG-PET to detect the large-vessel vascular inflammation was 89.5% (95% confidence interval [CI], 78.5–96.0) with pooled Sp at 97.7% (95% CI, 94–99), with a very high positive LR (28.7). There was no significant heterogeneity or inconsistency (Figure 1, Table 3).

FDG-PET for the Assessment of Large-Vessel Inflammation in TA

Seven studies were included in this second meta-analysis, including 191 patients with TA (N = 96 with active TA). The FDG-PET parameters used to detect the vascular inflammation were the visual analysis (n = 6 studies) and a semiquantitative analysis (n = 1) (Table 2). For the detection of large-vessel inflammation in TA according to the disease activity status (TA active/inactive disease as defined using NIH scale [n = 4 studies] or other [n = 3]), FDG-PET showed a pooled Se at 87% (95% CI, 78.0–92.6) and pooled Sp at 73% (95% CI, 62.5–81.3), with a positive LR at 4.2, and significant heterogeneity and inconsistency (I\textsuperscript{2} = 83.5%) (Figure 2 and Table 3). To explore the source of heterogeneity, we performed a subgroup analysis by combining the 4 studies with disease activity assessment based on NIH scale. The pooled Se remained similar at 84.4% (95% CI, 73.1–92.2) without heterogeneity (P = 0.196, I\textsuperscript{2} = 36%), and with an increased Sp at 84% (95% CI, 72.5–91.5%) (P = 0.134, I\textsuperscript{2} = 46.3%).

Correlation of FDG Vascular Uptake With Disease Activity in TA

Individual data of 78 patients with TA were extracted from 4 studies. Visual analysis was used for the detection of vascular inflammation in all studies, in addition to a semiquantitative analysis in 2/4 studies (Table 4). Visual grading correlated with the presence of clinical activity (P = 0.01), C-reactive protein (P = 0.04), and ESR levels (P = 0.04) (Table 4). SUV\textsubscript{max} ratio increased with the number of markers of disease activity (P = 0.01), and correlated with the presence of clinical activity (P = 0.01), ESR (P = 0.02), and C-reactive protein levels (P = 0.0006). Visual analysis showed that high uptake was well correlated with the presence of markers of activity: frequency of 8%, 21%, 56%, and 69% in the presence of 0, 1, 2, or 3 markers of activity. Interestingly, a significant vascular uptake (moderate and high uptakes) was observed in 67% (8/12) of TA patients without markers of activity versus 88% (14/16) in patients with the 3 markers of activity.
TA activity assessment using NIH scale

However, in the studies included in this meta-analysis, no comparison was made between FDG vascular uptake and findings of CTA. Consequently, the superiority of FDG-PET over CTA for the diagnosis of large-vessel inflammation in GCA cannot be determined so far. Other reasons could be argued to explain the high rate of FGD vascular uptake in GCA patients. The presence of atherosclerosis and increasing rate of vascular uptake with age could partly overestimate the rate of large-vessel inflammation in older patients. In the study of Tatsumi et al, including 85 consecutive patients with neoplasms, FDG uptake was commonly observed in the thoracic aortic wall, particularly in older patients, with hyperlipidemia or cardiovascular disease. Another point of discussion is the choice of PET criteria to define the presence of vascular inflammation, as no reliable parameter has been consensually defined yet. Our systematic review shows that the visual vascular uptake equal or higher than liver uptake was observed in 84% of LVV versus 18% controls (Table 2) and could constitute the PET criteria for the diagnosis of LVV. It is also important to note that the wall distribution of FDG uptake was not considered in the literature studies, and usually in LVV the lesions are circumferential while the atherosclerotic lesion is quite limited.

The second issue is the diagnosis of underlying vascular inflammation in TA. The definition of disease activity in TA is quite challenging, as radiological progression could be observed in patients without acute-phase reactants. Our study shows that PET allows a reliable assessment of inflammatory activity in TA, with a Se and Sp at 87% and 73%, respectively, and with a moderate increase in positive LR (4.2). Sp increased at 84% when considering patients with conventional disease activity assessment, that is NIH scale. Individual data analysis in TA patients showed that visual and semiquantitative analysis were helpful in the assessment of disease activity, as FDG uptake correlated with the presence of markers of inflammation. Yet, a moderate uptake was observed in a significant number of patients with inactive TA without any markers of inflammation (7/12, 58%, Table 4). This point is particularly important as it is well-established that disease activity is particularly difficult to ascertain, and previously postmortem histological studies showed a significant rate of vascular inflammation in patients considered to be having inactive TA disease. Indeed, active vascular inflammation could be found in patients with neither clinical nor biological activities, and imaging tools mostly consider the progression or new arterial lesions, but poorly correlate to the vascular inflammation. The assessment of vascular inflammation is a crucial issue, as it is correlated with arterial progression, and development of stenosis and thrombosis. Other prospective studies are needed to determine whether the presence of FDG uptake in patients without

### DISCUSSION

This study shows that FDG-PET has a good Se and Sp for the diagnosis of large-vessel inflammation in GCA patients and in TA patients. The performance of the FDG-PET is better in GCA patients than in TA patients (Se/Sp 90%/98% vs 84%/84%, respectively), with a higher positive LR (28.7 vs 4.2, respectively). This higher accuracy of PET in GCA could be explained by the inclusion of patients with GCA together with TA patients with various degrees of vascular inflammation.

These results are in line with previous reports, especially 1 previous meta-analysis including GCA patients showing pooled Se and Sp at 80% and 89%, respectively. The better performance of PET for the diagnosis of large-vessel inflammation in GCA found in our study can be explained by the inclusion of patients with ACR-positive GCA and with a precise definition of PET positivity. One recent study showed a Se of 80% and a Sp of 79% for the diagnosis of large-vessel inflammation in a case series of biopsy-proven GCA patients, using a semiquantitative analysis (mean of the SUV<sub>max</sub> at all the vascular territories).

Our results provide interesting data about the definition of vascular inflammation with FDG-PET. In GCA patients, a vascular uptake, equal or higher than the liver uptake, appears as the best criteria for the detection of vascular inflammation compared with controls. On the contrary, although our results showed a correlation between the intensity of FDG uptake and markers of activity in TA, a significant FDG vascular uptake can be observed in TA patients without markers of activity. Unfortunately, there is not enough literature data to compare the value of visual analysis versus semiquantitative analysis for the detection of vascular inflammation.

The aim of this study was to assess the value of FDG-PET in the management of both GCA and TA patients. The first issue is the diagnosis of large-vessel inflammation in confirmed GCA, because of the absence of validated imaging tool and the variable rate of large-vessel inflammation according to different studies. For this purpose, we included only studies with validated criteria for the diagnosis of GCA, and particularly, excluding patients with polymyalgia rheumatica without a confirmed diagnosis of associated GCA. Only studies with a precise description of PET parameters for the diagnosis of vascular inflammation were included, and studies which did not provide sufficient data were excluded. Using the review of the literature data, the frequency of large-vessel inflammation in GCA patients was determined at 87% and is much higher than the frequency usually described using Computed Tomography Angiography (CTA). The presence of aortitis in CTA varies between 20% and 65% in the literature.

### TABLE 3. Pooled Sensitivities and Specificities of the Meta-Analysis of the Values of FDG-PET for the Diagnosis of LVV in GCA and Disease Activity Assessment in TA

| Studies in GCA | Patients | Pooled Sensitivity | Pooled Specificity | AUC | PLR | NLR | DOR |
|---------------|----------|--------------------|-------------------|-----|-----|-----|-----|
| Diagnostic of LVV in GCA | 4 | 57 | 0.90 [0.79; 0.96] | 0.98 [0.94; 0.99] | 0.98 | 28.7 [11.5; 71.6] | 0.15 [0.07; 0.29] | 256.3 [70.8; 927] |
| TA activity assessment | 7 | 191 | 0.87 [0.78; 0.93] | 0.73 [0.63; 0.81] | 0.91 | 4.2 [1.5; 12] | 0.2 [0.1; 0.5] | 19.8 [4.5; 87.6] |
| TA activity assessment using NIH scale | 4 | 131 | 0.84 [0.73; 0.92] | 0.84 [0.73; 0.92] | 0.91 | 4.6 [2.1; 9.9] | 0.2 [0.1; 0.5] | 23.4 [5.2; 105.2] |

AUC = area under the curve, DOR = diagnostic odd ratio, FDG-PET = <sup>18</sup>F-fluorodeoxyglucose positron emission tomography, GCA = giant cell arteritis, LVV = large-vessels vasculitis, NIH = National Institutes of Health, NLR = negative likelihood ratio, PLR = positive likelihood ratio, TA = Takayasu arteritis.
FIGURE 2. FDG-PET for the disease activity in TA: forest plots of eligible studies show individual and pooled sensitivities and specificities of the studies included in the meta-analysis: (A): all studies with TA (B): studies with disease activity evaluated only with NIH scale. Inconsistency index squared was also determined. FDG-PET = \(^{18}\)F-fluorodeoxyglucose positron emission tomography, NIH = National Institutes of Health, TA = Takayasu arteritis.
clinically active disease could be correlated to the arterial progression, and thus vascular complications.

Our study has several biases, which could limit definitive conclusions. The main limitation of this meta-analysis is the different PET technologies used across studies, with about 50% (12/21) of studies using a nonhybrid technology. In addition, different parameters were used to define the presence of vascular inflammation, and this point underlines the need to standardize the PET criteria for LVV. Larger studies are needed to define accurate parameters to analyze the vascular inflammation by PET (visual analysis or semiquantitative or both), and define the threshold to ascertain the vascular inflammation. Other PET criteria, such as the pattern of FDG uptake (a circumferential uptake could be more consistent with vascular inflammation of LVV than atherosclerotic lesions), should be considered in order to increase the robustness of PET analysis.

Besides, the different conditions of the controls (infectious, inflammatory process, or malignancy) are another issue of this meta-analysis, and this point underlines the need to define accurate parameters to analyze the vascular inflammation, and this point underlines the need to standardize the PET criteria for LVV. Larger studies are needed to define accurate parameters to analyze the vascular inflammation by PET (visual analysis or semiquantitative or both), and define the threshold to ascertain the vascular inflammation. Other PET criteria, such as the pattern of FDG uptake (a circumferential uptake could be more consistent with vascular inflammation of LVV than atherosclerotic lesions), should be considered in order to increase the robustness of PET analysis.

There are remaining issues that should be addressed in future studies in order to increase the accuracy of FDG-PET in staging LVV, particularly the study of the FDG uptake patterns of extension and distribution in different arterial areas, as well as the correlation of FDG uptake with the CTA arterial wall thickening.

### CONCLUSIONS

FDG-PET appears to be a suitable modality for the detection of large-vessel inflammation in both GCA patients and TA patients. FDG-PET demonstrated a good performance in the diagnosis of large-vessel inflammation in GCA patients, with a pooled Se at 90% and a pooled Sp at 98%. In TA patients, FDG-PET showed an overall good accuracy for the assessment of disease activity with pooled Se and Sp at 84%. However, the presence of a significant vascular uptake can be observed in TA patients without markers of activity, and further studies are needed to determine whether it reflects infraclinical inflammation and correlates with arterial progression and vascular complications.

### TABLE 4. FDG Uptake Evaluated by Visual or Semiquantitative Analysis and Clinical and Biological Activity Criteria in 78 Patients With TA

| TA Disease Activity | Visual Grade | Semiquantitative Analysis |
|---------------------|--------------|---------------------------|
|                     | Slight       | Moderate                  | High          |
| No markers of activity<sup>a</sup> | 4 (33) | 7 (58) | 1 (8) | 0.88<sup>b</sup> |
| 1/3 markers of activity<sup>a</sup> | 8 (42) | 7 (37) | 4 (21) | 1.18 ± 0.62<sup>c</sup> |
| 2/3 markers of activity<sup>a</sup> | 4 (25) | 3 (19) | 9 (56) | 1.23 ± 0.34<sup>c</sup> |
| 3/3 markers of activity<sup>a</sup> | 2 (12) | 3 (19) | 11 (69) | 1.48 ± 0.68<sup>c</sup> |

FDG = <sup>18</sup>F-fluorodeoxyglucose, SUV<sub>max</sub> = maximum standardized uptake value, TA = Takayasu arteritis. Values are numbers with frequencies.

<sup>a</sup>Markers of disease activity among clinical activity, C-reactive protein >10 mg/L and ESR >20 mm/h.

<sup>b</sup>SUV<sub>max</sub> normalized by SUV of the liver.<sup>c</sup>

<sup>c</sup>SUV<sub>max</sub> ratio increased significantly with the number of markers of disease activity (P = 0.01).

### REFERENCES

1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* 2013;65:1–11.

2. Soussan M, Abisnor N, Abad S, et al. FDG-PET/CT in patients with ANCA-associated vasculitis: case-series and literature review. *Autoimmun Rev.* 2014;13:125–131.

3. Soussan M, Augier A, Brillet PY, et al. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features. *Clin Nucl Med.* 2013;38:e146–e159.

4. Soussan M, Brillet PY, Nunes H, et al. Clinical value of a high-fat and low-carbohydrate diet before FDG-PET/CT for evaluation of patients with suspected cardiac sarcoidosis. *J Nucl Cardiol.* 2012;20:120–127.

5. Ishimori T, Saga T, Mamede M, et al. Increased (18)F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. *J Nucl Med.* 2002;43:658–663.

6. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of [(1)F]-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* 2011;38:1764–1772.

7. Cheng Y, Lv N, Wang Z, et al. 18-FDG-PET in assessing disease activity in Takayasu arteritis: a meta-analysis. *Clin Exp Rheumatol.* 2013;31 (1 suppl 75):S22–S27.

8. Bertagna F, Bosio G, Caobelli F, et al. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for therapy evaluation of patients with large-vessel vasculitis. *Jpn J Radiol.* 2010;28:199–204.

9. Hooisma GA, Balink H, Houtman PM, et al. Parameters related to a positive test result for FDG PET/CT for large vessel vasculitis: a multicenter retrospective study. *Clin Rheumatol.* 2012;31:861–871.

10. de Souza AW, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis. *J Autoimmun.* 2014;48:49–79.8–3.

11. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med.* 1994;120:919–929.

12. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. *BMC Med Res Methodol.* 2006;6:31.

13. de Leeuw K, Bijl M, Jager PL. Additional value of positron emission tomography in diagnosis and follow-up of patients with large vessel vasculitides. *Clin Exp Rheumatol.* 2004;22 (6 suppl 36): S21–S26.
14. Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. *Eur J Nucl Med Mol Imaging*. 2012;39:344–353.

15. Lehmann P, Buchta S, Achajew N, et al. 18F-FDG PET as a diagnostic procedure in large vessel vasculitis—a controlled, blinded re-examination of routine PET scans. *Clin Rheumatol*. 2011;30:37–42.

16. Scheel AK, Meller J, Vossenrichr R, et al. Diagnosis and follow up of aortitis in the elderly. *Ann Rheum Dis*. 2004;63:1507–1510.

17. Walter MA, Melzer RA, Schindler C, et al. The value of [18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. *Eur J Nucl Med Mol Imaging*. 2005;32:674–681.

18. Blockmans D, Stroobants S, Maes A, et al. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. *Am J Med*. 2000;108:246–249.

19. Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. *Arthritis Rheum*. 2006;55:131–137.

20. Hautzel H, Sander O, Heinzel A, et al. Assessment of large-vessel involvement in giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff ratio. *J Nucl Med*. 2008;49:1107–1113.

21. Both M, Ahmadi-Simab K, Reuter M, et al. MRI and FDG-PET in the assessment of inflammatory aortic arch syndrome in complicated courses of giant cell arteritis. *Ann Rheum Dis*. 2008;67:1030–1033.

22. Czihal M, Tató F, Fösér S, et al. Fever of unknown origin as initial manifestation of large vessel giant cell arteritis: diagnosis by colour-coded sonography and 18-FDG-PET. *Clin Exp Rheumatol*. 2010;28:549–552.

23. Forster S, Tato F, Weiss M, et al. Patterns of extracranial involvement in newly diagnosed giant cell arteritis assessed by physical examination, colour coded duplex sonography and FDG-PET. *Vasa*. 2011;40:219–227.

24. Morinobu A, Tsuji G, Kasagi S, et al. Role of imaging studies in the diagnosis and evaluation of giant cell arteritis in Japanese: report of eight cases. *Mod Rheumatol*. 2011;21:391–396.

25. Meller J, Strutz F, Sieker U, et al. Early diagnosis and follow-up of aortitis with (18F)FDG PET and MRI. *Eur J Nucl Med Mol Imaging*. 2003;30:730–736.

26. Kobayashi Y, Ishii K, Oda K, et al. Aortic wall inflammation due to Takayasu arteritis imaged with 18F-FDG PET coregistered with enhanced CT. *J Nucl Med*. 2005;46:917–922.

27. Andrews J, Al-Nahas A, Pennell DJ, et al. Non-invasive imaging in the diagnosis and management of Takayasu’s arteritis. *Ann Rheum Dis*. 2004;63:995–1000.

28. Webb M, Chambers A, Al-Nahas A, et al. The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. *Eur J Nucl Med Mol Imaging*. 2004;31:627–634.

29. Lee SG, Ryu JS, Kim HO, et al. Evaluation of disease activity using F-18 FDG PET-CT in patients with Takayasu arteritis. *Clin Nucl Med*. 2009;34:749–752.

30. Arnaud L, Haroche J, Malek Z, et al. Is (18F)-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? *Arthritis Rheum*. 2009;60:1193–1200.

31. Lee KH, Cho A, Choi YJ, et al. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. *Arthritis Rheum*. 2012;64:866–875.

32. Tezuka D, Haraguchi G, Ishihara T, et al. Role of FDG PET-CT in Takayasu arteritis: sensitive detection of recurrences. *JACC Cardiovasc Imaging*. 2012;5:422–429.

33. Karapolat I, Kalfa M, Keser G, et al. Comparison of F18-FDG PET/ CT findings with current clinical disease status in patients with Takayasu’s arteritis. *Clin Exp Rheumatol*. 2012;31(1 Suppl 75):S15–S21.

34. Prieto-Gonzalez S, Depetris M, Garcia-Martinez A, et al. Positron emission tomography assessment of large vessel inflammation in patients with newly diagnosed, biopsy-proven giant cell arteritis: a prospective, case-control study. *Ann Rheum Dis*. 2014;73:1388–1392.

35. Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. *Ann Rheum Dis*. 2012;71:1170–1176.

36. Vista EG, Santos Estrella PV, Lichaouco JJ. Fluorine-18 fluorodeoxyglucose positron emission tomography as a non-invasive test of disease activity in Takayasu’s arteritis—a report of four cases. *Autoimmun Rev*. 2010;9:503–506.

37. Janssen SP, Comans EH, Voskuyl AE, et al. Giant cell arteritis: heterogeneity in clinical presentation and imaging results. *J Vasc Surg*. 2008;48:1025–1031.

38. Henes JC, Muller M, Krieger J, et al. [18F] FDG-PET/CT as a new and sensitive imaging method for the diagnosis of large vessel vasculitis. *Clin Exp Rheumatol*. 2008;26(3 suppl 49):S47–S52.

39. Brodmann M, Lipp RW, Passath A, et al. The role of 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of giant cell arteritis of the temporal arteries. *Rheumatology (Oxford)*. 2004;43:241–242.

40. Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. *Ann Rheum Dis*. 2012;71:1170–1176.

41. Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. *Arthritis Rheum*. 2008;59:422–430.

42. Tatsumi M, Cohade C, Nakamoto Y, et al. Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis. *Radiology*. 2003;229:831–837.

43. Hoffman GS, Ahmed AE. Surrogate markers of disease activity in patients with Takayasu arteritis. A preliminary report from The International Network for the Study of the Systemic Vasculitides (INSSYS). *Int J Cardiol*. 1998;66 (suppl 1):S191–S194 discussion S195.